Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment

Andrea Mancuso,E. Donato De Paola,A. Catalano,Fabio Calabrò,C. Messina,Andrea Zivi,Linda Cerbone,Leonardo Vigna,Rita Caristo,Cora N. Sternberg

Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment

2009

Andrea Mancuso
E. Donato De Paola
A. Catalano
Fabio Calabrò
C. Messina
Andrea Zivi
Linda Cerbone
Leonardo Vigna
Rita Caristo
Cora N. Sternberg

e16027 Background: Sorafenib is an orally active multikinase inhibitor (Raf kinase, VEGFR 1, 2, 3 and PDGFR inhibitor) for the treatment of advanced RCC. The purpose of this study was to assess the...

Keywords:

Renal cell carcinoma
Cancer research
Internal medicine
Sorafenib
Oncology
VEGF receptors
Medicine
in patient
dose escalation
prior treatment
Platelet-derived growth factor receptor
vegfr tki
orally active

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations